Antibody therapies for the prevention and treatment of viral infections

被引：135

作者：

Salazar, Georgina ^{[1
]}

Zhang, Ningyan ^{[1
]}

Fu, Tong-Ming ^{[2
]}

An, Zhiqiang ^{[1
]}

机构：

[1] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Texas Therapeut Inst, Brown Fdn, Houston, TX 77030 USA

[2] Merck & Co Inc, Merck Res Labs, Kenilworth, NJ USA

来源：

NPJ VACCINES | 2017年 / 2卷

关键词：

HUMAN MONOCLONAL-ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS; POTENT NEUTRALIZING ANTIBODIES; MEMORY B-CELLS; INFLUENZA-A; HUMAN CYTOMEGALOVIRUS; DENGUE VIRUS; SINGLE-CELL; STRUCTURAL BASIS; DOUBLE-BLIND;

D O I：

10.1038/s41541-017-0019-3

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host-viral interaction and viral pathogenesis mechanisms and to find potential cures for viral infection and disease. With more than 60 recombinant monoclonal antibodies developed for human use in the last 20 years, monoclonal antibodies are now considered a viable therapeutic modality for infectious disease targets, including newly emerging viral pathogens such as Ebola representing heightened public health concerns, as well as pathogens that have long been known, such as human cytomegalovirus. Here, we summarize some recent advances in identification and characterization of monoclonal antibodies suitable as drug candidates for clinical evaluation, and review some promising candidates in the development pipeline.

引用

页数：12

共 154 条

[1]

Ansun Biopharma I., 2014, RAND DOUBL BLIND PLA

[2] Kinetics of influenza A virus infection in humans [J].

Baccam, Prasith ;

Beauchemin, Catherine ;

Macken, Catherine A. ;

Hayden, Frederick G. ;

Perelson, Alan S. .

JOURNAL OF VIROLOGY, 2006, 80 (15) :7590-7599

[3] First administration to humans of a monoclonal antibody cocktail against rabies virus: Safety, tolerability, and neutralizing activity [J].

Bakker, A. B. H. ;

Python, C. ;

Kissling, C. J. ;

Pandya, P. ;

Marissen, W. E. ;

Brink, M. F. ;

Lagerwerf, F. ;

Worst, S. ;

van Corven, E. ;

Kostense, S. ;

Hartmann, K. ;

Weverling, G. J. ;

Uytdehaag, F. ;

Herzog, C. ;

Briggs, D. J. ;

Rupprecht, C. E. ;

Grimaldi, R. ;

Goudsmit, J. .

VACCINE, 2008, 26 (47) :5922-5927

[4] Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants [J].

Bakker, ABH ;

Marissen, WE ;

Kramer, RA ;

Rice, AB ;

Weldon, WC ;

Niezgoda, M ;

Hanlon, CA ;

Thijsse, S ;

Backus, HHJ ;

de Kruif, J ;

Dietzschold, B ;

Rupprecht, CE ;

Goudsmit, J .

JOURNAL OF VIROLOGY, 2005, 79 (14) :9062-9068

[5] Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption [J].

Bar, K. J. ;

Sneller, M. C. ;

Harrison, L. J. ;

Justement, J. S. ;

Overton, E. T. ;

Petrone, M. E. ;

Salantes, D. B. ;

Seamon, C. A. ;

Scheinfeld, B. ;

Kwan, R. W. ;

Learn, G. H. ;

Proschan, M. A. ;

Kreider, E. F. ;

Blazkova, J. ;

Bardsley, M. ;

Refsland, E. W. ;

Messer, M. ;

Clarridge, K. E. ;

Tustin, N. B. ;

Madden, P. J. ;

Oden, K. S. ;

O'Dell, S. J. ;

Jarocki, B. ;

Shiakolas, A. R. ;

Tressler, R. L. ;

Doria-Rose, N. A. ;

Bailer, R. T. ;

Ledgerwood, J. E. ;

Capparelli, E. V. ;

Lynch, R. M. ;

Graham, B. S. ;

Moir, S. ;

Koup, R. A. ;

Mascola, J. R. ;

Hoxie, J. A. ;

Fauci, A. S. ;

Tebas, P. ;

Chun, T-W .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21) :2037-2050

[6] The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome [J].

Baranovich, Tatiana ;

Jones, Jeremy C. ;

Russier, Marion ;

Vogel, Peter ;

Szretter, Kristy J. ;

Sloan, Susan E. ;

Seiler, Patrick ;

Trevejo, Jose M. ;

Webby, Richard J. ;

Govorkova, Elena A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (04) :2118-2131

[7] The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity [J].

Beltramello, Martina ;

Williams, Katherine L. ;

Simmons, Cameron P. ;

Macagno, Annalisa ;

Simonelli, Luca ;

Quyen, Nguyen Than Ha ;

Sukupolvi-Petty, Soila ;

Navarro-Sanchez, Erika ;

Young, Paul R. ;

de Silva, Aravinda M. ;

Rey, Felix A. ;

Varani, Luca ;

Whitehead, Stephen S. ;

Diamond, Michael S. ;

Harris, Eva ;

Lanzavecchia, Antonio ;

Sallusto, Federica .

CELL HOST & MICROBE, 2010, 8 (03) :271-283

[8] Maintenance of serological memory by polyclonal activation of human memory B cells [J].

Bernasconi, NL ;

Traggiai, E ;

Lanzavecchia, A .

SCIENCE, 2002, 298 (5601) :2199-2202

[9] Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak [J].

Bornholdt, Zachary A. ;

Turner, Hannah L. ;

Murin, Charles D. ;

Li, Wen ;

Sok, Devin ;

Souders, Colby A. ;

Piper, Ashley E. ;

Goff, Arthur ;

Shamblin, Joshua D. ;

Wollen, Suzanne E. ;

Sprague, Thomas R. ;

Fusco, Marnie L. ;

Pommert, Kathleen B. J. ;

Cavacini, Lisa A. ;

Smith, Heidi L. ;

Klempner, Mark ;

Reimann, Keith A. ;

Krauland, Eric ;

Gerngross, Tillman U. ;

Wittrup, Karl D. ;

Saphire, Erica Ollmann ;

Burton, Dennis R. ;

Glass, Pamela J. ;

Ward, Andrew B. ;

Walker, Laura M. .

SCIENCE, 2016, 351 (6277) :1078-1083

[10] A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis [J].

Borucki, MJ ;

Spritzler, J ;

Asmuth, DM ;

Gnann, J ;

Hirsch, MS ;

Nokta, M ;

Aweeka, F ;

Nadler, PI ;

Sattler, F ;

Alston, B ;

Nevin, TT ;

Owens, S ;

Waterman, K ;

Hubbard, L ;

Caliendo, A ;

Pollard, RB .

ANTIVIRAL RESEARCH, 2004, 64 (02) :103-111

← 1 2 3 4 5 6 7 8 9 10 →